India, Aug. 25 -- Generate Biomedicines Inc. (GENB), a clinical-stage generative biology company, recently reported second-quarter 2026 financial results and provided updates across its clinical pipeline and strategic collaborations.
Revenue for the second quarter was $6.3 million, compared with $10.1 million in the prior-year quarter.
Research and development expenses increased to $64.3 million from $59.7 million, primarily reflecting continued investment in the Phase 3 SOLAIRIA trials of GB-0895 in severe asthma.
General and administrative expenses rose to $13.6 million from $10.5 million, driven primarily by higher stock-based compensation.
Net loss widened to $67.3 million, or approximately $0.52 per share, compared with a net loss ...